Memorial Sloan Kettering Cancer Center

Lenvatinib plus pembrolizumab improved outcomes vs. chemotherapy for women with advanced endometrial cancer, according to findings presented at the virtual Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

Electroacupuncture and auricular acupuncture led to greater pain reductions than usual care among cancer survivors with chronic musculoskeletal pain, according to results of a randomized clinical trial published in JAMA Oncology.

The Parker Institute for Cancer Immunotherapy awarded nearly $3 million worth of grants to six early career researchers.

At the start of his ASH presidency and a year into the COVID-19 pandemic, Martin S. Tallman, MD, reflected on the challenges the pandemic has presented to his field.

Adjuvant nivolumab extended DFS compared with placebo among patients with high-risk, muscle invasive urothelial carcinoma, according to results of the phase 3 CheckMate 274 trial presented at Genitourinary Cancers Symposium.

The combination of lenvatinib and pembrolizumab significantly prolonged OS and PFS compared with sunitinib among previously untreated patients with advanced renal cell carcinoma, according to results of the phase 3 CLEAR trial.

Sotorasib conferred durable clinical benefit for patients with pretreated advanced non-small cell lung cancer who harbor KRAS G12C mutations.

Ivosidenib modestly extended OS among patients with previously treated isocitrate dehydrogenase 1-mutated advanced cholangiocarcinoma, according to final results of the phase 3 ClarIDHy trial presented at Gastrointestinal Cancers Symposium.

Pembrolizumab monotherapy demonstrated superior PFS and PFS2 compared with standard-of-care chemotherapy among patients with microsatellite-instability high/mismatch repair-deficient metastatic colorectal cancer.

National Association for Proton Therapy created a physician advisory committee to provide advice on topics such as clinical research, patient education and insurance reimbursement.